Current Psychiatry Reports

, 13:323 | Cite as

Dietary and Nutritional Treatments for Attention-Deficit/Hyperactivity Disorder: Current Research Support and Recommendations for Practitioners

  • Elizabeth A. HurtEmail author
  • L. Eugene Arnold
  • Nicholas Lofthouse


Evidence for dietary/nutritional treatments of attention-deficit/hyperactivity disorder (ADHD) varies widely, from double-blind, placebo-controlled trials to anecdotal. In guiding patients, clinicians can apply the SECS versus RUDE rule: treatments that are Safe, Easy, Cheap, and Sensible (SECS) require less evidence than those that are Risky, Unrealistic, Difficult, or Expensive (RUDE). Two nutritional treatments appear worth general consideration: Recommended Daily Allowance/Reference Daily Intake multivitamin/mineral supplements as a pediatric health intervention not specific to ADHD and essential fatty acids, especially a mix of eicosapentaenoic acid, docosahexaenoic acid, and γ-linolenic acid as an ADHD-specific intervention. Controlled studies support the elimination of artificial food dyes to reduce ADHD symptoms, but this treatment may be more applicable to the general pediatric population than to children with diagnosed ADHD. Mineral supplementation is indicated for those with documented deficiencies but is not supported for others with ADHD. Carnitine may have a role for inattention, but the evidence is limited. Dimethylaminoethanol probably has a small effect. Herbs, although “natural,” are actually crude drugs, which along with homeopathic treatments have little evidence of efficacy. Consequences of delayed proven treatments need consideration in the risk–benefit assessment of dietary/nutritional treatments.


ADHD Complementary and alternative medicine Dietary treatments Nutritional treatments Recommendations 



Dr. Arnold has served as a consultant for Shire, the Neuropharm Group, Organon Pharmaceuticals, Targacept, AstraZeneca, Seaside Therapeutics, Novartis, and Noven Pharmaceuticals; has received grant support from Shire, Curemark, and Eli Lilly and Company; and has given continuing medical education presentations supported by Shire.

Drs. Hurt and Lofthouse reported no potential conflicts of interest relevant to this article.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders (revised 4th ed.). Washington: American Psychiatric Association; 2000.Google Scholar
  2. 2.
    Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004;14:11–28.PubMedCrossRefGoogle Scholar
  3. 3.
    Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40:168–79.PubMedCrossRefGoogle Scholar
  4. 4.
    National Center for Complementary and Alternative Medicine Publication No. D347 (2007). What is CAM? Available at Accessed November 2010.
  5. 5.
    Kemper KJ, O’Connor KG. Pediatricians’ recommendations for complementary and alternative medical (CAM) therapies. Ambul Pediatr. 2004;4:482–7.PubMedCrossRefGoogle Scholar
  6. 6.
    •• Arnold LE, Hurt EA, Mayes T, Lofthouse N. Ingestible alternative and complementary treatments for attention-deficit/hyperactivity disorder. In: Hoza B, Evans, SW, editors. Treating attention-deficit disorder. Kingston: Civic Research Institute; 2011. This chapter provides an evaluation of the current research support for ingestible CAM treatments of pediatric ADHD. Google Scholar
  7. 7.
    Chan E, Rappaport LA, Kemper KJ. Complementary and alternative therapies in childhood attention and hyperactivity problems. J Dev Behav Pediatr. 2003;24:4–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Benton D, Roberts G. Effect of vitamin and mineral supplementation on intelligence of a sample of schoolchildren. Lancet. 1988;331:140–3.CrossRefGoogle Scholar
  9. 9.
    Benton D, Cook R. Vitamin and mineral supplements improve the intelligence scores and concentration of six-year-old children. Personal Individ Differ. 1991;12:1151–8.CrossRefGoogle Scholar
  10. 10.
    Crombie IK, Flory C, Todman J, et al. Effect of vitamin and mineral supplementation on verbal and nonverbal reasoning of schoolchildren. Lancet. 1990;335:744–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Benton D, Buts JP. Vitamin/mineral supplementation and intelligence. Lancet. 1990;335:1158–60.PubMedCrossRefGoogle Scholar
  12. 12.
    McCann D, Barrett A, Cooper A, et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:1560–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Stevens LJ, Zentall SS, Deck JL, et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr. 1995;62:761–8.PubMedGoogle Scholar
  14. 14.
    Spahis S, Vanasse M, Belanger SA, et al. Lipid profile, fatty acid composition and pro- and anti-oxidant status in pediatric patients with attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids. 2008;79:47–53.PubMedCrossRefGoogle Scholar
  15. 15.
    Brookes KJ, Chen W, Xu X, et al. Association of fatty acid desaturase genes with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;60:1053–61.PubMedCrossRefGoogle Scholar
  16. 16.
    Belanger SA, Vanasse M, Spahis S, et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatr Child Health. 2009;14:89–98.PubMedGoogle Scholar
  17. 17.
    Gustafsson PA, Birberg-Thornberg U, Duchen K, et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr. 2010;99:1540–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Arnold LE, Kleykamp D, Votolato NA, et al. Gamma-linolenic acid for attention-deficit/hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biol Psychiatry. 1989;25:222–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Calarge C, Farmer C, DiSilvestro R, Arnold LE. Serum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2010;20:495–502.PubMedCrossRefGoogle Scholar
  20. 20.
    Oner P, Oner O. Relationship of ferritin to symptom ratings children with attention deficit hyperactivity disorder: effect of comorbidity. Child Psychiatry Hum Dev. 2008;39:323–30.PubMedCrossRefGoogle Scholar
  21. 21.
    Sever Y, Ashkenazi A, Tyano S, Weizman A. Iron treatment in children with attention-deficit/hyperactivity disorder: a preliminary report. Neuropsychobiology. 1997;35:178–80.PubMedCrossRefGoogle Scholar
  22. 22.
    Konofal E, Lecendreux M, Deron J, et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol. 2008;38:20–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Conners CK. Food additives and hyperactive children. London: Plenum; 1980.Google Scholar
  24. 24.
    National Institutes of Health. NIH consensus development conference: defined diets and childhood hyperactivity. Clin Pediatr. 1982;21:627–30.CrossRefGoogle Scholar
  25. 25.
  26. 26.
    Pelsser LM, Frankena K, Toorman J, et al. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. Lancet. 2011;377:494–503.PubMedCrossRefGoogle Scholar
  27. 27.
    Bateman B, Warner JO, Hutchinson E, et al. The effects of a double blind, placebo controlled artificial food colourings and benzoate preservative challenge on hyperactivity in a general population sample of preschool children. Arch Dis Child. 2004;89:506–11.PubMedCrossRefGoogle Scholar
  28. 28.
    Van Oudheusden LJ, Scholte HR. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids. 2002;67:33–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Arnold LE, Amato A, Bozzolo H, et al. Acetyl-L-Carnitine in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol. 2007;17:791–801.PubMedCrossRefGoogle Scholar
  30. 30.
    Abbasi SH, Heidari S, Mohammadi MR, et al. Acetyl-l-carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a placebo-controlled trial. Child Psychiatry Hum Dev 2011, published online ahead of print.Google Scholar
  31. 31.
    Ferrari R, Merli E, Ciccitelli G, et al. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci. 2004;1033:79–91.PubMedCrossRefGoogle Scholar
  32. 32.
    Re O. 2- Dimethylaminoethanol (deanol): a brief review of its clinical efficacy and postulated mechanism of action. Curr Therap Res Clin Exp. 1974;16:1238–42.Google Scholar
  33. 33.
    Lewis JA, Young R. Deanol and methylphenidate in minimal brain dysfunction. Int J Clin Pharmacol Ther. 1975;17:534–40.Google Scholar
  34. 34.
    Arnold LE, Votolato NA, Kleykamp D, et al. Does hair zinc predict amphetamine improvement of ADHD/hyperactivity? Int J Neurosci. 1990;50:103–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Bilici M, Yildirim F, Kandil S, et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:181–90.PubMedCrossRefGoogle Scholar
  36. 36.
    Uckardes Y, Ozmert EN, Unal F, Yurdakok K. Effects of zinc supplementation on parent and teacher behavior rating scores in low socioeconomic level Turkish primary school children. Acta Paediatri. 2009;98:731–6.CrossRefGoogle Scholar
  37. 37.
    Akhondzadeh S, Mohammadi M, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. BMC Psychiatry. 2004;4.Google Scholar
  38. 38.
    • Arnold LE, DiSilvestro RA, Bozzolo D, et al. Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. J Child Adolesc Psychopharmacol 2011;21:1–19. This article is one of the few studies to evaluate CAM treatments as complementary treatments to standard stimulant medication. PubMedCrossRefGoogle Scholar
  39. 39.
    Kozielec T, Starobrat-Hermelin B, Kotkowiak L. Deficiency of certain trace elements in children with hyperactivity. Psychiatria Polska. 1994;28:345–53.PubMedGoogle Scholar
  40. 40.
    Mousain-Bosc M, Roche M, Poige A, et al. Improvements of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. Magnes Res. 2006;19:46–52.PubMedGoogle Scholar
  41. 41.
    Mousain-Bosc M, Roche M, Rapin J, Bali JP. Magnesium VitB6 intake reduces central nervous system hyperexcitability in children. J Am Coll Nutr. 2004;23:545S–8S.PubMedGoogle Scholar
  42. 42.
    Nogovitsina OR, Levitina EV. Neurological aspects of the clinical features, pathophysiology, and corrections of impairments in attention deficit hyperactivity disorder. Neurosci Biol Psychiatry. 2007;37:199–202.Google Scholar
  43. 43.
    Starobrat-Hermelin B, Kozielec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention-deficit/hyperactivity disorder (ADHD): positive response to magnesium oral loading test. Magnes Res. 1997;10:149–56.PubMedGoogle Scholar
  44. 44.
    Izenwasser SE, Garcia-Valdez K, Kantak KM. Stimulant-like effects of magnesium on aggression in mice. Pharmacol Biochem Behav. 1986;25:1195–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Durlach J, Durlach V, Bac P, et al. Magnesium and therapeutics. Magnes Res. 1994;7:313–28.PubMedGoogle Scholar
  46. 46.
    Dykman KD, Dykman RA. Effect of nutritional supplements on attentional-deficit hyperactivity disorder. Integr Physiol Behav Sci. 1998;33:49–60.PubMedCrossRefGoogle Scholar
  47. 47.
    Dykman KD, McKinley R. Effect of Glyconutritionals on the severity of ADHD. Proc Fish Inst Med Res. 1997;1:24–5.Google Scholar
  48. 48.
    Kaplan BJ, Fisher JE, Crawford SG, et al. Improved mood and behavior during treatment with a mineral-vitamin supplement: an open-label case series of children. J Child Adolesc Psychopharmacol. 2004;14:115–22.PubMedCrossRefGoogle Scholar
  49. 49.
    • Rucklidge J, Taylor M, Whitehead K. Effect of micronutrients on behavior and mood in adults with ADHD: evidence from an 8-week open label trial with natural extension. J Attent Disord 2011;15:79–91. This article is one of the few studies to evaluate CAM treatments for adults with ADHD. PubMedCrossRefGoogle Scholar
  50. 50.
    Harding KL, Judah RD, Gant CE. Outcome-based comparison of Ritalin versus food-supplement treated children with ADHD. Altern Med Rev. 2003;8:319–30.PubMedGoogle Scholar
  51. 51.
    Krummel DA, Seligson FH, Guthrie HA. Hyperactivity: is candy causal? Crit Rev Food Sci Nutr. 1996;36:31–47.PubMedCrossRefGoogle Scholar
  52. 52.
    Wolraich ML, Lindgren SD, Stumbo PJ, et al. Effects of diets high in sucrose or aspartame on the behavior and cognitive performance of children. N Engl J Med. 1994;330:301–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Wesnes KA, Pincock C, Richardson D, et al. Breakfast reduces declines in attention and memory over the morning in schoolchildren. Appetite. 2003;41:329–31.PubMedCrossRefGoogle Scholar
  54. 54.
    Bornstein RA, Baker GB, Carroll A, et al. Plasma amino acids in attention deficit disorder. Psychiatry Res. 1990;33:301–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Stein TP, Sammaritano AM. Nitrogen metabolism in normal and hyperkinetic boys. Am J Clin Nutr. 1984;39:520–4.PubMedGoogle Scholar
  56. 56.
    Nemzer E, Arnold LE, Votolato NA, McConnell H. Amino Acid supplementation as therapy for attention deficit disorder (ADD). J Am Acad Child Adolesc Psychiatry. 1986;25:509–13.CrossRefGoogle Scholar
  57. 57.
    Zametkin AJ, Karoum F, Rapoport J. Treatment of hyperactive children with d-phenylalanine. Am J Psychiatry. 1987;144:792–4.PubMedGoogle Scholar
  58. 58.
    Arnold LE, Christopher J, Huestis RD, Smeltzer DJ. Megavitamins for minimal brain dysfunction: a placebo-controlled study. JAMA. 1978;240:2642–3.PubMedCrossRefGoogle Scholar
  59. 59.
    Brenner A. The effects of megadoses of selected B complex vitamins on children with hyperkinesis; controlled studies with long-term follow-up. J Learn Disabil. 1982;15:258–64.PubMedCrossRefGoogle Scholar
  60. 60.
    Canadian Paediatric Society. Megavitamin and megamineral therapy in childhood. Can Med Assoc J. 1990;143:1009–113.Google Scholar
  61. 61.
    McGuire JK, Kulkarni MS, Baden HP. Fatal hypermagnesemia in a child treated with megavitamin/megamineral therapy. Pediatrics. 2000;105:E18.PubMedCrossRefGoogle Scholar
  62. 62.
    Trebaticka J, Kopasova S, Hradecna Z, et al. Treatment of ADHD with French maritime pine bark extract, Pycnogenol. Eur Child Adolesc Psychiatry. 2006;15:329–35.PubMedCrossRefGoogle Scholar
  63. 63.
    Tenenbaum S, Paull JC, Sparrow EP, et al. An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). J Atten Disord. 2002;6:49–60.PubMedCrossRefGoogle Scholar
  64. 64.
    Weber W, Stoep AV, McCarty RL, et al. Hypericum perforatum (St John’s Wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. JAMA. 2008;299:2633–41.PubMedCrossRefGoogle Scholar
  65. 65.
    Salehi B, Imani R, Mohammadi MR, et al. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:76–80.PubMedCrossRefGoogle Scholar
  66. 66.
    Lyon MR, Cline JC, De Zepetnek JT, et al. Effect of the herbal extract combination Panax quinquefolium and Ginkgo biloba on attention-deficit hyperactivity disorder: a pilot study. J Psychiatry Neurosci. 2001;26:221–8.PubMedGoogle Scholar
  67. 67.
    Katz M, Levine AA, Kol-Degani H, Kav-Venaki L. A compound herbal preparation (CHP) in the treatment of children with ADHD: a randomized controlled trial. J Atten Disord. 2010;14:281–91.PubMedCrossRefGoogle Scholar
  68. 68.
    Lamont J. Homeopathic treatment of attention deficit hyperactivity disorder. Br Homeopath J. 1997;86:196–200.CrossRefGoogle Scholar
  69. 69.
    Frei H, Everts R, von Ammon K, et al. Homeopathic treatment of children with attention deficit hyperactivity disorder: a randomised, double blind, placebo controlled crossover trial. Eur J Pediatr. 2005;164:758–67.PubMedCrossRefGoogle Scholar
  70. 70.
    Strauss LC. The efficacy of a homeopathic preparation in the management of attention deficit hyperactivity disorder. J Biomed Ther. 2000;18:197–201.Google Scholar
  71. 71.
    Jacobs J, Williams AL, Girard C, et al. Homeopathy for attention-deficit/hyperactivity disorder: a pilot randomized-controlled trial. J Altern Complement Med. 2005;11:799–806.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Elizabeth A. Hurt
    • 1
    Email author
  • L. Eugene Arnold
    • 2
  • Nicholas Lofthouse
    • 3
  1. 1.Nisonger CenterThe Ohio State UniversityColumbusUSA
  2. 2.Nisonger CenterThe Ohio State UniversityColumbusUSA
  3. 3.Department of PsychiatryThe Ohio State UniversityColumbusUSA

Personalised recommendations